Intravenous β‐lactam antibiotics remain a cornerstone in the management of bacterial
infections due to their broad spectrum of activity and excellent tolerability. β‐lactams are well …

Physiologic alterations seen in obesity commonly impact the pharmacokinetics (PK) and
pharmacodynamics (PD) of antibiotics and may result in suboptimal dosing in this …

Introduction: Obesity is associated with many physiological changes. We review available
evidence regarding five commonly accepted assumptions to a priori predict the impact of …

Introduction Obesity is associated with many physiological changes. We review available
evidence regarding five commonly accepted assumptions to a priori predict the impact of …

Objective: Dose optimization of novel β-lactam antibiotics (NBLA) has become necessary
given the increased prevalence of multidrug-resistant infections in intensive care units …

The objectives of this study were to describe meropenem pharmacokinetics (PK) in plasma
and/or subcutaneous adipose tissue (SCT) in critically ill patients receiving extracorporeal …

Drug dosing in obese patients continues to be challenging due to a lack of high‐quality
evidence to guide dosing recommendations. We first published guidance for antibiotic …

Purpose This study aimed to develop a population pharmacokinetic (PPK) model for
meropenem to optimize dosing regimens for critically ill patients with pulmonary infection …

Childhood obesity and its associated comorbidities are highly prevalent diseases that may
add to any other possible health problem commonly affecting the pediatric age …

Background: This controlled clinical study aimed to investigate the impact of obesity on
plasma and tissue pharmacokinetics of meropenem. Methods: Obese (body mass index …